New Medication for Treatment-Resistant Depression Available

The Rochester Center for Behavioral Medicine welcomes the approval of Spravato (esketamine), a novel medication manufactured by Janssen that is used adjunctively with anti-depressant medications for treatment-resistant depression. Our medical director, Dr. Joel Young, was a primary investigator during the Spravato clinical trial. If you are interested in being considered for this new treatment, please email  We will contact you once our program is up and running!

Please note:

  • -We will be offering this treatment in the Spring of 2019
  • -This treatment is approved for adults ages 18 and older
  • -Prescribing clinicians will determine the need for treatment with objective assessments
  • -Treatment is dependent upon factors that vary with each individual
  • -Insurance coverage varies based on individual health plan 

Spravato featured in the New York Times